product summary
Loading...
company name :
Krishgen Biosystems
product type :
ELISA/assay
product name :
KRIBIOLISA™ Cetuximab ELISA (HERCEPTIN)
catalog :
KBI1018
quantity :
1 x 96 wells
price :
750 USD
more info or order :
product information
Catalog Number :
KBI1018
Product Name :
KRIBIOLISA™ Cetuximab ELISA (HERCEPTIN)
Product Type :
ELISA
Size :
1 x 96 wells
List Price (USD) :
750 USD
Product Description :
Sensitivity: 80 ng/ml
Sample Type: Serum, Plasma
Calibrator Range: 0 - 640 ng/ml
Enzyme Immunoassay for the Quantitative Determination of Cetuximab in serum and plasma.
Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion that is distributed under the trade name Erbitux in the U.S. and Canada by the drug company Bristol-Myers Squibb and outside the U.S. and Canada by the drug company Merck KGaA. In Japan, Merck KGaA, Bristol-Myers Squibb and Eli Lilly have a co-distribution. In July 2009, FDA approved Cetuximab (Erbitux) for treatment of colon cancer with wild-type KRAS, since it had little or no effect in colorectal tumors harboring a KRAS mutation (this also applied to the EGFR antibody panitumumab).
Krishgen PK kits, developed using the innovator drug as calibrator, are used for the quantitation of serum protein drug levels, and can be used for biosimilar and generics research as well.
About the kit:
- Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
- Recovery rates are between 85 - 115%
- Ready to use with a standard protocol with break-apart pre-coated wells
- Validated as per US FDA guidelines for Bioassays
- Optimized for matrix effects to ensure higher sensitivity.
- Shelf life: 1 year
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Cetuximab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Cetuximab present in the sample are bound by the capture antibody. Then a HRP (horseradish peroxidase) conjugated anti-Cetuximab antibody is pipetted and incubated. After washing microwells in
order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Cetuximab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
SpeciesSummary :
Human
Background :
Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion that is distributed under the trade name Erbitux in the U.S. and Canada by the drug company Bristol-Myers Squibb and outside the U.S. and Canada by the drug company Merck KGaA. In Japan, Merck KGaA, Bristol-Myers Squibb and Eli Lilly have a co-distribution. In July 2009, FDA approved Cetuximab (Erbitux) for treatment of colon cancer with wild-type KRAS, since it had little or no effect in colorectal tumors harboring a KRAS mutation (this also applied to the EGFR antibody panitumumab).
Packaging :
This ELISA kit comes with a pre-coated plate, concentrated or lyophilized standards, wash solution, subtrate, stop solution and all the required diluents. For the exact contents of the kit, please refer to the datasheet / IFU.
Storage :
2-8 Deg C
Calibration Range :
0 ng/ml - 640 ng/ml
Sensitivity :
80ng/ml
Assay Principle :
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Cetuximab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Cetuximab present in the sample are bound by the capture antibody. Then a HRP (horseradish peroxidase) conjugated anti-Cetuximab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Cetuximab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
Biomarker :
Cetuximab
Regulatory Status :
CE IVD
Shipping :
2-8 degrees C
more info or order :
company information

Krishgen Biosystems
11331 183rd Street, #413
Cerritos, CA 90703
Cerritos, CA 90703
sales_usa@krishgen.com
http://www.krishgen.com1-888-970-0827
headquarters: USA
related products
browse more products
questions and comments